About this resource:
Source: The Cochrane Collaborative
Last Reviewed: October 2018
In this Cochrane systematic review, the Cochrane Collaborative found that anti-vascular endothelial growth factor medicines prevent vision loss and improve vision in people with diabetic macular edema. These medicines — aflibercept, bevacizumab, and ranibizumab — are injected into the eye to slow the growth of new blood vessels and reduce swelling at the back of the eye. Researchers found some evidence that aflibercept is more effective than bevacizumab and ranibizumab.
Objectives related to this resource (1)
Virgili, G., Parravano, M., Evans, J. R., Gordon, I., & Lucenteforte, E. (2018). Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database of Systematic Reviews, 2018 (6). DOI: 10.1002/14651858.CD007419.pub6.